Our interviewees this month explain their roles in efforts to enhance drug safety. Recent high-profile issues with drug safety have highlighted the need not only to improve post-marketing ...

The safety profile was also encouraging. Almost all treatment-emergent adverse events were mild to moderate. No grade 3 or higher adverse event was considered to be drug-related. In the ongoing ...